Basilea guidance for 2026 now calls for approximately CHF 115 million in operating profit, up from CHF 70 million previously, as the Swiss drugmaker expects higher revenue from its Cresemba and Zevtera products. The company announced the revision on October 27, 2026, alongside updates on two late-stage clinical programs.
Key Takeaways
- Basilea raised its 2026 forecast for Cresemba and Zevtera-related revenue to about CHF 250 million from CHF 210 million.
- Its 2026–2030 cumulative cash flow target for the two products increased to CHF 650 million from CHF 600 million.
- The company plans to start a combined phase 2/3 study of ceftibuten-ledaborbactam in mid-2027.
Basilea guidance reflects higher milestone income
Basilea said a significant increase in expected milestone income supported the higher outlook. It now expects approximately CHF 65 million in milestone payments in 2026, compared with CHF 35 million previously.
The company forecasts total 2026 revenue of approximately CHF 310 million and research and development expenses of about CHF 125 million. These figures are guidance, not completed full-year results.
| Item | Details |
|---|---|
| 2026 Cresemba and Zevtera-related revenue | Approximately CHF 250 million, versus approximately CHF 210 million previously |
| 2026 cash contribution from the two products | Approximately CHF 215 million, versus approximately CHF 180 million previously |
| 2026 milestone payments | Approximately CHF 65 million, versus approximately CHF 35 million previously |
| 2026–2030 cumulative cash flow target | CHF 650 million, versus CHF 600 million previously |
Clinical programs move forward
Following consultations with the US Food and Drug Administration and European Medicines Agency, Basilea plans a combined phase 2/3 study of ceftibuten-ledaborbactam for complicated urinary tract infections, without a separate confirmatory phase 3 study. It expects a phase 2 data readout as early as the end of 2028.
For fosmanogepix, Basilea said it completed recruitment into the salvage therapy cohort of its invasive mold infection study. Recruitment continues in the study’s other cohorts and in a separate invasive candidiasis study. The company expects phase 3 readouts in mid-2028 and plans to include both studies in its initial regulatory filings.
Next milestone
Basilea is scheduled to provide a further strategic update at its Capital Markets Day in Zurich on October 28, 2026.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…